Abstracts tagged "Mesenchymal stem cells"

Abstract Number: 2134 • 2016 ACR/ARHP Annual Meeting
Bone Replaces Cartilage in Non-Weight Bearing Regions of Immobilized Knees
T Mark Campbell¹, Katherine Reilly², Odette Laneuville³, Hans Uhthoff⁴ and Guy Trudel⁵, ¹Physical Medicine and Rehabilitation, Elisabeth Bruyere Hospital, Ottawa, ON, Canada, ²Medicine, University of Ottawa, Ottawa, ON, Canada, ³Biology, University of Ottawa, Ottawa, ON, Canada, ⁴Surgery, The Ottawa Hospital, Ottawa, ON, Canada, ⁵Medicine, The Ottawa Hospital Rehabilitation Centre, Ottawa, ON, Canada
Bone Replaces Cartilage In Non-Weight Bearing Regions Of Immobilized KneesBackground/Purpose: Osteoarthritis causes pain, restricts joint range of motion, reduces function, is highly prevalent worldwide and…
Abstract Number: 2623 • 2016 ACR/ARHP Annual Meeting
Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase 1, Proof-of-Concept Clinical Trial
Dong Jin Go¹, Hee-suk Lim², Ahrmi Cho³, Kyounghwan Roh³, Kwang-Won Seo³, Kyung-Sun Kang^3,4 and Kichul Shin⁵, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea, ³Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, Korea, The Republic of, ⁴Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Korea, The Republic of, ⁵Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Background/Purpose: The immunomodulatory actions of human umbilical cord blood (hUCB)-derived mesenchymal stem cells (MSCs) in rheumatoid arthritis (RA) have been studied extensively via in vitro…
Abstract Number: 793 • 2015 ACR/ARHP Annual Meeting
Mesenchymal Stem Cells Promote the Generation of CD206+ Macrophage and Increase Its Phagocytic Activity in Systemic Lupus Erythematosus
Wei Deng, Weiwei Chen, Zhuoya Zhang, Saisai Huang, Wei Kong, Yue Sun, Xuebing Feng, Xiaojun Tang, Genhong Yao and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have been confirmed to exert therapeutic effects on systemic lupus erythematosus (SLE). Deficiency in SLE macrophages exhibits…
Abstract Number: 2563 • 2015 ACR/ARHP Annual Meeting
Immune Regulation By Migrating Mesenchymal Stem Cells Ameliorate Inflammatory Arthritis in Mice
Seung Min Jung, Yoojun Nam and Ji Hyeon Ju, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Mesenchymal stem cells (MSCs) function as immune regulators in inflammatory conditions. However, it is unclear how to control local inflammation by systemically administered MSCs. We…
Abstract Number: 2703 • 2015 ACR/ARHP Annual Meeting
Reduction in Matrix Metalloproteinase-1 and -2 Secretion from Fibroblast-like Synoviocytes after Induction of Adipogenesis By a Natural Peroxisome Proliferator-Activated Receptor Gamma Ligand, Arterpilin-C
Eiji Sugiyama¹, Satoshi Yamasaki¹ and Je-Tae Woo^2,3, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Department of Biological Chemistry, Chubu University, Aichi, Japan, ³JT WOO, Okinawa Research Center Co., Ltd, Okiawa, Japan
Background/Purpose: Fibroblast-like synoviocytes (FLS) play important roles in rheumatoid arthritis (RA) by producing matrix metalloproteinase (MMP) and cytokines, and hence, these cells are a therapeutic…
Abstract Number: 3180 • 2015 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Treatment in Juvenile Idiopathic Arthritis: A Pilot Study
Joost Swart¹, Nico Wulffraat², Berent J. Prakken³, Ineke Slaper-Cortenbach⁴ and Caroline Lindemans⁵, ¹PO Box 85090, UMC Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center, Utrecht, Netherlands, ⁴Cell Therapy Facility, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a frequent childhood disease with a prevalence of 1 per 1000 children. The introduction of the biological agents including…
Abstract Number: 2361 • 2014 ACR/ARHP Annual Meeting
the Role of CD146 in the Therapeutic Potential of Mesenchymal Stem Cells in Favor of CD146⁺ Cells for Experimental Arthritis
Deh-Ming Chang¹ and Cheng-Chi Wu², ¹Rheumatology/Immunology, Taipei Veteran's General Hospital, Taipei, Taiwan, ²National Defense Medical Center, Taipei, Taiwan
Background/Purpose: To illustrate whether the subtypes of mesenchymal stem cells (MSCs) have different cellular characteristics and therapeutic potentials, we separated CD146+/- mesenchymal stem cells and…
Abstract Number: 1969 • 2014 ACR/ARHP Annual Meeting
Neurotrophin Receptor p75 (CD271) Defines a Distinct Synovial Fibroblast Subset in Rheumatoid and Osteoarthritic Synovial Tissues with Enhanced Proinflammatory Potential
Manuel J. Del Rey¹, Regina Faré¹, Gabriel Criado², Alicia Usategui¹, Vanessa Miranda¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose Synovial mesenchynmal or stromal cells constitute a heterogeneous cell population difficult to characterize ex vivo due to a paucity of cell markers and are…
Abstract Number: 1007 • 2014 ACR/ARHP Annual Meeting
Markedly Increased Mesenchymal Stem Cell Activity in MRI Bone Marrow Lesions Compared with Non-Involved Bone in Osteoarthritic Hips
T Mark Campbell¹, Frederique Ponchel², Alexandro Gomez³, Richard J. Hodgson², Dennis McGonagle⁴, Philip G. Conaghan⁵ and Elena Jones³, ¹Medicine, The Ottawa Hospital Rehabilitation Centre, Ottawa, ON, Canada, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Musculoskeletal Biomedical Research Unit, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, United Kingdom
Background/Purpose Multipotent mesenchymal stem cells (MSCs) are critical for bone and cartilage repair but the role of such cells in vivo in hip OA is…
Abstract Number: 35 • 2014 ACR/ARHP Annual Meeting
Hydrogen Sulfide Inhibits Human Osteoclast Differentiation in Vitro By Triggering Sustained Antioxidant Response and Inhibiting the RANKL/OPG Ratio
Francesco Grassi¹, Laura Gambari², Andrea Facchini³ and Gina Lisignoli⁴, ¹LAB. RAMSES, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, ²Lab. RAMSES, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, ³Lab of Immunorheumatology and Tissue Regeneration, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, ⁴LAB. OF IMMUNORHEUMATOLOGY AND TISSUE REGENERATION, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy
Background/Purpose Hydrogen sulfide (H2S) has been recently appreciated as a novel gasotransmitter with an important role in the regulation of tissues and organs. H2S is…
Abstract Number: 29 • 2014 ACR/ARHP Annual Meeting
Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis – Anti-Inflammatory Therapy As Confounder
Annemarie Lang¹, Sarah Fuegener², Paula Hoff², Anastasia Rakow³, Manuela Jakstadt⁴, Timo Gaber⁴, Gerd Burmester², Carsten Perka³ and Frank Buttgereit⁵, ¹Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Center for Musculoskeletal Surgery, Orthopedic Department, Charité University Medicine, Berlin, Germany, ⁴Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose Anti-inflammatory treatment of rheumatoid arthritis (RA) with glucocorticoids (GC) and/or non-steroidal anti-inflammatory drugs (NSAIDs) is supposed to negatively influence bone metabolism and healing. It…
Abstract Number: 2644 • 2013 ACR/ARHP Annual Meeting
Phase IB/Iia Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients
JM Alvaro-Gracia¹, Juan A. Jover², Rosario Garcia-Vicuña³, Luis Carreño⁴, Alberto Alonso⁵, Sara Marsal⁶, Francisco J. Blanco⁷, Víctor M. Martínez-Taboada⁸, Peter C. Taylor⁹, Federico Díaz-González¹⁰ and Lydia Dorrego¹¹, ¹Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁵Hospital de Cruces, Bilbao, Spain, ⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁷INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ⁹NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁰Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ¹¹TiGenix, Tres Cantos, Spain
Background/Purpose: Expanded adipose-derived stem cells (eASCs) are shown to have immune-modulatory effects both in vitro and in animal models of arthritis. eASCs are currently under…
Abstract Number: 1590 • 2013 ACR/ARHP Annual Meeting
A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE
Dandan Wang¹, Lin Lu², Xuebing Feng³, Xia Li² and Lingyun Sun³, ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Mesenchymal stem cells (MSC) show therapeutic effects on human autoimmune diseases including systemic…
Abstract Number: 62 • 2013 ACR/ARHP Annual Meeting
Tenogenic Effect Of Homeobox Mohawk gene for Bone Marrow Mesenchymal Stem Cells
Koji Otabe¹, Hiroyuki Nakahara¹, Akihiko Hasegawa¹, Martin K. Lotz¹ and Hiroshi Asahara², ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²Molecular & Experimental Med, The Scripps Research Institute, La Jolla, CA
Background/Purpose: Mohawk homeobox (MKX) has been demonstrated as a tendon and ligament specific transcriptional factor. MKX knock-out mice showed hypoplastic tendons throughout the body, due…
Abstract Number: 46 • 2013 ACR/ARHP Annual Meeting
Alarmins S100A8/A9 Regulate Osteophyte Formation In Experimental Osteoarthritis With High Synovial Activation
Rik Schelbergen¹, Arjen B. Blom¹, Wouter de Munter¹, Annet W. Sloetjes², Thomas Vogl³, Johannes Roth⁴, Wim B. van den Berg⁵ and Peter L.E.M. van Lent¹, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ³Institute of Immunology, University of Muenster, Muenster, Germany, ⁴Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Osteophytes are cartilage capped, bony outgrowths that limit joint movement and originate from the periosteum or from ligaments during osteoarthritis (OA). There is increasing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].